HIV increases the risk of cancer, 1 and the incidence of lymphoma among people living with HIV (PLWH) is higher than in the general population. 2 Before the availability of combined antiretroviral therapy (cART), HIV-associated lymphoma (HIV+Ly) was associated with a poor prognosis as treatment options were limited due to the toxicity of chemotherapy and the significant risk of opportunistic infections. The introduction of cART in 1996, along with better management of opportunistic infections, and the use of CSFs to support higher-dose intensity combination chemotherapy, has led to improved survival among patients with HIV+Ly. 3 The survival rates for HIV+Ly among PLWH are comparable to HIV-negative patients treated for Hodgkin lymphoma, Burkitt lymphoma and diffuse large B-cell lymphoma. 4, 5 However, as in the general population, there is a proportion of lymphomas that do not respond or relapse following first-line chemotherapy. High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been the standard approach for refractory and relapsed lymphoma since the late 1990s based on phase III clinical trials. 6, 7 The information regarding salvage options for patients with refractory or relapsed HIV-associated lymphoma (r-HIV+Ly) comes from retrospective studies. 8, 9 In general, salvage chemotherapy regimens used as second-line treatment of r-HIV+Ly prior to ASCT are individualised and are based on trials in the HIV-negative population, where no regimen has been shown to be superior to others, but platinum-based combination chemotherapy, such as DHAP (dexamethasone, cytarabine and cisplatin), is generally used.
Since around 2000, the same approach including ASCT has been adopted by several groups for r-HIV+Ly. 10 A total of 222 cases of ASCT for HIV+Ly have been assembled from the world literature by Re et al., 10 although this includes 18 patients in first remission who did not have r-HIV+Ly. The follow-up in the various cohorts varies, but after excluding studies that included patients in first remission, the overall survival of transplanted patients ranges from 36 to 87%. 11, 12 However, these studies have only included patients who have undergone ASCT, and only a single study has evaluated outcomes of r-HIV+Ly by an intention to treat with ASCT, and found that nearly 46% patients did not get as far as ASCT. 13 We reviewed the demographics of patients diagnosed with r-HIV+Ly and compared the outcomes of those who were treated with an intention to proceed to ASCT (ITT) and those who underwent ASCT.
At the National Centre for HIV Malignancies at the Chelsea and Westminster Hospital, London, we prospectively collect routine data on all individuals who attend. All HIV seropositive patients diagnosed with lymphoma between 1986 and 2015 were included in the study. The study population was divided into those who relapsed and did not proceed to ASCT, those who received salvage chemotherapy with an intention to treat with ASCT and those who were treated with ASCT following salvage chemotherapy. Demographic information was obtained for all three groups; however, response and survival outcomes were obtained for those who had an intention to treat with ASCT and those who completed ASCT. The overall survival was calculated from the date of r-HIV+Ly diagnosis until the date of death or last follow-up.
Of the 628 patients diagnosed with HIV+Ly within our centre between 1986 and 2015, 113 (18%) developed r-HIV-Ly. Curative salvage treatment was not administered to 69 patients due to diagnosis of r-HIV-Ly prior to 2000 (38), central nervous system involvement by lymphoma at relapse (24), and co-morbidities (7) such as myelodysplasia and progressive multifocal leukoencephalopathy. Salvage chemotherapy was given to 44 patients with the intention to subsequently treat with high-dose chemotherapy and ASCT, though 24 patients progressed or died prior to ASCT. Twenty patients underwent stem cell harvesting; however, 2 patients failed mobilisation and 18 had high-dose conditioning chemotherapy and ASCT. Table 1 demonstrates the histological subtypes and salvage chemotherapy regimens administered to patients treated with an intent to transplant and those who completed ASCT. Combination antiretroviral regiments included non-nucleoside reverse transcriptase inhibitors in 45%, integrase inhibitors in 32% and protease inhibitors in 20% of patients treated with salvage chemotherapy with an intention to proceed to transplantation.
The mean CD4+ lymphocyte cell count at the start of ASCT was 287 cells/mm 3 Figure 1) . Compared with the start of ASCT, there was no statistically significant change in the CD4+ lymphocyte count at 1, 6 and 12 months after ASCT (P = 0.67, P = 0.20 and P = 0.32); however, there was a significant rise in the CD4+ lymphocyte after 3 and 5 years (P = 0.02 and P = 0.03). The mean CD4+ lymphocyte percentage at ASCT was 23% (95% CI: 17-28%) and there was statistically significant reduction in the CD4+ lymphocyte percentage 6 months following ASCT 16% (95% CI: 14-19%, P = 0.05). However, there was no significant change in the mean CD4+ lymphocyte percentage at ASCT compared with 1 month, 12 months, 3 years and 5 years (P = 0.10, P = 0.61, P = 0.20 and P = 0.35).
Response was assessed with positron emission tomographycomputerised tomography (PET-CET) in 31 patients (70%) who received salvage chemotherapy with an intention to proceed to ASCT. Among patients treated with an intention to treat with ASCT, achieving a complete response on imaging following salvage chemotherapy was a prognostic factor (hazard ratio (HR) 0.21 (95% CI: 0.09-0.51), P o0.05)); however, histological subtype was not a significant factor (HR 0.79 (95% CI: 0.47-1.33, P = 0.38). Radiological assessment was obtained 2 months after ASCT. Thirteen patients had a complete metabolic response (72%) on PET-CT assessment, one patient had a partial response and four patients (22%) progressed following ASCT. Four patients (22%) had low-grade uptake in single sites from the initial assessment post ASCT. In each of these cases, radiotherapy was administered and resulted in a clinical response, and subsequent PET-CT demonstrated complete metabolic response. Among all patients who were treated with salvage chemotherapy with an intention to transplant, lymphoma relapse was the cause of death in 26 patients (59%) and among all patients who died following ASCT.
The 2-and 5-year overall survivals for the 26 patients who were commenced on salvage chemotherapy with an intention to proceed to ASCT were 15% (95% CI: 0-34%) and 10% (95% CI: 0-21%). For the 18 patients who had ASCT, the 2-year overall survival after ASCT was 74% (95% CI: 45-89%) and this remained the same 5 years following ASCT. No deaths occurred more than 1 year after ASCT.
From our initial cohort of 113 with r-HIV+Ly, 44 patients with r-HIV+Ly eligible for ASCT were treated with salvage chemotherapy, 20 (45%) achieved adequate lymphoma cytoreduction and were candidates for PBSC mobilisation. This is a value similar to that achieved by one published study that assessed feasibility of salvage chemotherapy followed by conditioning high-dose chemotherapy and ASCT in r-HIV+Ly. 13 Adequate numbers of CD34+ stem cells were harvested from 18 (90%) patients. A pan-European study of stem cell mobilisation in 155 patients with HIV+Ly (including 17 patients in this series) found that adequate harvesting was achieved in 73%.
14 These findings confirm the feasibility of this approach in r-HIV+Ly as 41% patients in our cohort with an intention to treat with ASCT completed salvage chemotherapy and proceeded to stem cell harvesting, induction chemotherapy and ASCT. Therefore, the rate of attrition in this study was only 41% in those undergoing ASCT, and in the only other series describing the whole cohort approach the attrition rate was 54%. 13 For the 18 patients who had ASCT, the 2-and 5-year overall survival after ASCT was 74% and this is similar to the published results in other cohorts of r-HIV+Ly. [11] [12] [13] 15, 16 The safety of ASCT in r-HIV-Ly was a major concern due to potential harm from opportunistic infection as assessed by non-relapse mortality (NRM), and the subsequent effects of ASCT on immune function and CD4+ lymphocyte subsets. Four patients who completed ASCT have died, all due to lymphoma relapse. Several other series of ASCT have also reported 0% NRM in HIV+Ly, 11, 13, 17 while other series report an NRM of 5-33%. 12, 15, [18] [19] [20] A nonsignificant fall in CD4+ cell count was observed during the salvage chemotherapy prior to harvesting, but no further decline was observed during the ASCT, and counts rose significantly by 3 Abbreviations: BL = Burkitt lymphoma; DHAP = dexamethasone, cytarabine and cisplatin; DLBCL = diffuse large B-cell lymphoma; PEL = primary effusion lymphoma; R-DHAP = rituximab, dexamethasone, cytarabine and cisplatin; R-IVE = rituximab, ifosfamide, epirubicin and etoposide. Salvage treatment regimens and imaging response prior to and following ASCT. a All patients including those treated with salvage chemotherapy and ASCT.
and 5 years following ASCT. These findings will reassure both clinicians and patients that this clinical strategy for r-HIV+Ly is safe in the short and intermediate terms.
There are limitations to this single-centre study such as the relatively small number of patients that proceed to ASCT. The small study number also limits analysis of prognostic factors in ASCT and there are confounders that cannot be accounted for within the survival analyses. Despite these limitations, our study supports the view that ASCT is a feasible and safe treatment option for patients with r-HIV+Ly. 
